scholarly journals Association Between Plasma Irisin in Mid-Pregnancy and Postpartum Glucose Levels Among Chinese Women

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1086-1086
Author(s):  
Nu Tang ◽  
Yajun Chen ◽  
Weijia Wu ◽  
Jingshu Zhang ◽  
Kaiyun Tan ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Quantile Regression ◽  
Chinese Women ◽  
Fasting Blood Glucose ◽  
Postprandial Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Glucose Levels ◽  
Modifiable Factors ◽  
Pregnancy And Postpartum

Abstract Objectives The association between plasma irisin and glucose levels in general population was controversial and few researches longitudinally explored this correlation. We aimed to examine whether mid-pregnancy irisin was associated with postpartum glucose among Chinese women and explore the potential modifiable factors. Methods We conducted a prospective cohort study in Guangzhou, China during 2017–2018 and 453 pregnant women (20–28 weeks) were enrolled. At 6–8 weeks after birth, 94 women with gestational diabetes mellitus (GDM) underwent a 75 g oral glucose tolerance test, and the other 359 women had a fasting blood glucose (FBG) test. Multivariable linear regression, quantile regression, and logistic regression analysis were conducted. Results Mean baseline plasma irisin was 13.73 ng/ml. The prevalence of postpartum impaired fasting glucose (IFG) was 14.35% in all participants. Among women with previous GDM, 23 (24.47%) had impaired glucose tolerance (IGT). We found a significantly negative association between mid-pregnancy irisin and postpartum FBG (β: −0.056 ± 0.024). While quantile regression showed the associations were only significant in high percentiles of FBG (P50 to P95), and the magnitude displayed an increasing trend. In addition, higher baseline irisin was associated with lower risk of postpartum IFG (RR, 0.563; CI, 0.384–0.825). Furthermore, we detected significant interactions between irisin and breastfeeding on FBG and IFG (both Pinteraction < 0.05). But baseline irisin was not significantly associated with postpartum postprandial glucose levels or the risk of IGT in women with GDM. Conclusions Plasma irisin levels during mid-pregnancy were negatively associated with FBG and IFG at 6–8 weeks postpartum among Chinese women, and stronger associations in women with higher FBG values were observed. Moreover, breastfeeding may modify this relationship. Funding Sources This work was supported by the National Natural Science Foundation of China (81,602,862) and the Sanming Project of Medicine in Shenzhen (SZSM201803061).

The diagnosis of diabetes mellitus

1983 ◽  
Vol 104 (4_Suppl) ◽  
pp. S11-S17
Author(s):  
Bengt Scherstén ◽  
Per-Olof Bitzén
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Glucose Levels ◽  
Asymptomatic Subject ◽  
Blood Glucose Levels

ABSTRACT. The procedure for diagnosing diabetes mellitus when accompanied by classical symptoms is based on random blood glucose levels of 7 mmol/l or more. Problem of diagnosing diabetes in the asymptomatic subject remains difficult. A procedure based on fasting blood glucose levels below 5.5 mmol/l in normals and reproducible values at or above 7 mmol/l in diabetics is proposed. In cases with fasting blood glucose values between 5.5 and 7 mmol/l standardized oral glucose tolerance test is recommended. The diagnostic criteria for normality, impaired glucose tolerance and for diabetes are evaluated against the results of a 10–14 years prospective study.

scholarly journals Glucose Homeostasis in Patients with Pheochromocytoma

2013 ◽  
Vol 20 (1) ◽  
pp. 63-67
Author(s):  
Rucsandra Dănciulescu Miulescu ◽  
Denisa Margină ◽  
Mirela Culman ◽  
Sorin Păun ◽  
Cătălina Poiană
Keyword(s):  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Surgical Removal ◽  
Family History Of Diabetes ◽  
Glucose Levels ◽  
Before And After ◽  
History Of

Abstract Background and Aims. Previous studies have shown that impaired glucose tolerance is present in patients with pheochromocytoma with a prevalence of 25- 75%. The aim of this study was to examine glucose tolerance in 12 patients with pheochromocytoma, before and after medical and surgical treatment. Material and Methods. We evaluated 12 patients aged between 44 and 60 years with confirmed pheochromocytoma. Plasma insulin, fasting blood glucose and 2h glucose levels during the oral glucose tolerance test (OGTT) were measured before and three months after surgical removal of the tumor. Results. Surgical removal of the tumor generated significant changes in plasma and urinary metanephrines (plasma normetanephrine 191.15±13.22 pg/ml after treatment vs. 792.54±86.74 pg/ml at baseline, p<0.0001, plasma metanephrine 86.69±4.48 pg/ml vs. 363.62.±21.69 pg/ml, p<0.0001, urinary normetanephrine 718.54±37.59 μg/day after treatment vs. 1855.77±116.54 μg/day at baseline and urinary metanephrine of 258.31±34.00 μg/day vs. 745.38±65.14 μg/day, p<0.0001) but not in insulin, fasting and 2h glucose levels during OGTT. Conclusion. In our study, the prevalence of impaired glucose tolerance in patients with confirmed pheochromocytoma was 8.33% (1 patient with a previous family history of diabetes). After surgical removal of the tumor, normalization of mean glucose levels of OGTT was not achieved.

Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individualsThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.

2007 ◽  
Vol 85 (9) ◽  
pp. 856-864 ◽  
Author(s):  
Anamaria Dascalu ◽  
John L. Sievenpiper ◽  
Alexandra L. Jenkins ◽  
Mark P. Stavro ◽  
Lawrence A. Leiter ◽  
...  
Keyword(s):  
Fasting Blood Glucose ◽  
Area Under The Curve ◽  
Postprandial Glucose ◽  
American Ginseng ◽  
Tolerance Test ◽  
Ginseng Root ◽  
Oral Glucose ◽  
Natural Health Products ◽  
Water Control ◽  
Postprandial Glycemia

Evidence indicates that the glycemia-lowering effect of American ginseng root may be batch dependent. We therefore evaluated the effect of 5 root batches, representative of Ontario-grown American ginseng, on postprandial glucose and insulin indices. Twelve healthy subjects (5 male, 7 female), mean ± SE age 26.5 ± 2 years, body mass index 23.96 ± 3.41 kg/m2, fasting blood glucose 4.77 ± 0.04 mmol/L, were assigned to consume 9 g of American ginseng from 5 farms (A–E), administered in randomized sequence on 5 separate visits, and a water-control during the 6th and last visit. Treatments were consumed 40 min before a 2-hour 75-gram oral glucose tolerance test. Plasma glucose and insulin were measured at baseline, before, and during the test. Compared with control, batches A and C reduced glucose incremental area under the curve (IAUC) by 35.2% (156 vs. 240 mmol·min/L) and 32.6% (162 vs. 240 mmol·min/L), respectively. Batches A, C, and E reduced incremental peak glucose by 1.3, 1.2, and 1.1 mmol/L, respectively. Batch C reduced the insulin IAUC by 27.7% (15.8 vs. 21.8 nmol·min/L). Effects on glucose and insulin parameters were not different across ginseng treatments. The mean of the 5 ginseng treatments reduced peak postprandial glucose by 1.0 mmol/L, glucose IAUC by 27.7% (173 vs. 240 mmol·min/L), and insulin IAUC by 23.8% (16.6 vs. 21.8 nmol·min/L) relative to control. (All results statistically significant at p < 0.05.) American ginseng decreased postprandial glycemia and insulinemia; however, 40% of the batches did not reduce glycemia with the anticipated magnitude, irrespective of their saponin composition.

scholarly journals Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0249239
Author(s):  
Jason A. West ◽  
Anastasia Tsakmaki ◽  
Soumitra S. Ghosh ◽  
David G. Parkes ◽  
Rikke V. Grønlund ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Fasting Blood Glucose ◽  
Chronic Administration ◽  
Dual Therapy ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Beneficial Effects ◽  
Gut Hormone ◽  
Gip Receptor

Combinatorial gut hormone therapy is one of the more promising strategies for identifying improved treatments for metabolic disease. Many approaches combine the established benefits of glucagon-like peptide-1 (GLP-1) agonism with one or more additional molecules with the aim of improving metabolic outcomes. Recent attention has been drawn to the glucose-dependent insulinotropic polypeptide (GIP) system due to compelling pre-clinical evidence describing the metabolic benefits of antagonising the GIP receptor (GIPR). We rationalised that benefit might be accrued from combining GIPR antagonism with GLP-1 agonism. Two GIPR peptide antagonists, GIPA-1 (mouse GIP(3–30)NH2) and GIPA-2 (NαAc-K10[γEγE-C16]-Arg18-hGIP(5–42)), were pharmacologically characterised and both exhibited potent antagonist properties. Acute in vivo administration of GIPA-1 during an oral glucose tolerance test (OGTT) had negligible effects on glucose tolerance and insulin in lean mice. In contrast, GIPA-2 impaired glucose tolerance and attenuated circulating insulin levels. A mouse model of diet-induced obesity (DIO) was used to investigate the potential metabolic benefits of chronic dosing of each antagonist, alone or in combination with liraglutide. Chronic administration studies showed expected effects of liraglutide, lowering food intake, body weight, fasting blood glucose and plasma insulin concentrations while improving glucose sensitivity, whereas delivery of either GIPR antagonist alone had negligible effects on these parameters. Interestingly, chronic dual therapy augmented insulin sensitizing effects and lowered plasma triglycerides and free-fatty acids, with more notable effects observed with GIPA-1 compared to GIPA-2. Thus, the co-administration of both a GIPR antagonist with a GLP1 agonist uncovers interesting beneficial effects on measures of insulin sensitivity, circulating lipids and certain adipose stores that seem influenced by the degree or nature of GIP receptor antagonism.

scholarly journals GESTATIONAL DIABETES MELLITUS

2012 ◽  
Vol 19 (04) ◽  
pp. 462-468
Author(s):  
M. IKRAM ◽  
SYED HAIDER HASAN ALAM ◽  
SHAFQAT MUKHTAR ◽  
M. Saeed
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Gestational Diabetes ◽  
Glucose Tolerance ◽  
Gestational Diabetes Mellitus ◽  
Glucose Tolerance Test ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance

Introduction: Gestational diabetes mellitus is common disorder in pregnancy. It is associated with adverse pregnancy outcome. There is no consensus regarding the optimal approach to screening of gestational diabetes mellitus. The present study has tried toobserve the value of fasting blood glucose in screening of gestational diabetes. Objective: To determine the frequency of patients in whomfasting blood glucose and 100gm glucose tolerance show agreement for screening of gestational diabetes mellitus at 24 -28 wks. Studydesign: Comparative cross sectional study. Settings: The study was conducted at Gynecology and Obstetrics department Shaikh ZayedFederal Post Graduate Institute Lahore. Duration of study with dates: 6 months from 12Nov 2010 to 11 May 2011. Material and method: Thestudy included 135 booked patients with positive family history of diabetes mellitus. All patients underwent fasting blood glucose at 24-28 weeksof gestation, regardless of results of fasting blood glucose on next visit they underwent 100g oral glucose tolerance test (OGTT). The agreementbetween fasting blood glucose and 100g oral glucose tolerance test was calculated in frequency and percentages. Results: The mean age ofwomen in studied population was 27.15±3.70.Out of 135 patients 86.7 %( 117) showed agreement between results of fasting blood glucose and100g OGTT while 13.31 %( 18) showed no agreement between both of the tests. Conclusions: Fasting blood glucose is a good screeningoption for gestational diabetes mellitus along with positive history. It provides a simple, cheap and more practical test for screening of gestationaldiabetes mellitus. However diagnostic confirmation with 100g OGTT should be done.

scholarly journals Compound Danshen Dripping Pills Prevented Leptin Deficiency-Induced Hepatic ER Stress, Stimulated Autophagy, and Improved Insulin Resistance of ob/ob Mice

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Yanan Shi ◽  
Dan Liu ◽  
Jihong Yuan ◽  
Lihui Yan ◽  
Zhenfeng Zhan ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Glucose Tolerance ◽  
Er Stress ◽  
Heart Diseases ◽  
Fasting Blood Glucose ◽  
Underlying Mechanism ◽  
Hepatic Function ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Signal Sensitivity

Compound Danshen dripping pills (CDDP) is widely used for the treatment of coronary arteriosclerosis and ischemic heart diseases for decades of years. In our study, we interestingly discovered the effects and mechanism of CDDP on insulin resistance that increase the risk factor of cardiovascular diseases. Effects of CDDP on fasting blood glucose, the insulin tolerance test (ITT), the oral glucose tolerance test (OGTT), hepatic function, and underlying mechanism were analyzed in ob/ob mice. CDDP was found improving the impaired insulin signal sensitivity of ob/ob mice by ameliorating insulin and glucose tolerance, improving hepatic phosphorylation of the insulin receptor substrate-1 on Ser 307 (pIRS1) of ob/ob mice, and restoring hepatic function by decreasing serum ALT and AST, which increased in ob/ob mice serum. Decreasing hepatic phosphorylation of pancreatic ER kinase (PERK) and inositol-requiring enzyme-1 (IRE1) regulating hepatic ER stress in the liver of ob/ob mice were increased by CDDP. Furthermore, CDDP was also found stimulating ob/ob mice hepatic autophagy by increasing the expression of Beclin1 and LC3B, while decreasing P62 expression. Our study discovered an important role of CDDP on improving ob/ob mice insulin resistance and liver function probably through relieving hepatic ER stress and stimulating hepatic autophagy, which would broaden the application value and provide more benefits for treating cardiovascular patients. This trial is registered with NCT01659580.

scholarly journals Preliminary phytochemical screening and evaluation of hypoglycemic properties of the root extract of Uveria chamae

2015 ◽  
Vol 10 (2) ◽  
pp. 326 ◽  
Author(s):  
Emordi Jonathan Emeka ◽  
Agbaje Esther Oluwatoyin ◽  
Oreagba Ibrahim Adekunle ◽  
Iribhogbe Osede Ignis
Keyword(s):  
Single Dose ◽  
Blood Glucose ◽  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Phytochemical Screening ◽  
Glucose Levels ◽  
Blood Glucose Levels

<p>The purpose of this study is to evaluate the hypoglycaemic properties and preliminary phytochemical screening of <em>Uveria chamae</em>. The hypoglycaemic properties of <em>Uveria chamae</em> was assessed on normoglycaemic rat that received single dose of the extract at 250 and 500 mg/kg body weight and blood glucose levels estimated at 2, 4, and 6 hours (single dose study). The hypoglycaemic property of the extract was also evaluated in normoglycemic rats by oral glucose tolerance test. Phytochemical screening of the extract for the presence of secondary metabolites was performed with standard methods. The extract showed a significant (p&lt;0.05) reduction in blood glucose levels at 2h and 6h compared to control.  The oral glucose tolerance test  result also showed a significant decrease (p&lt;0.05) in blood glucose levels . The study showed that the extract, <em>Uveria chamae</em> has hypoglycaemic properties which may be accounted for by the presence of the phytochemicals.</p><p> </p>

scholarly journals Metabolic phenotype in Darier disease: a cross-sectional clinical study

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Tara Ahanian ◽  
Philip Curman ◽  
Ivone U. S. Leong ◽  
Kerstin Brismar ◽  
Etty Bachar-Wikstrom ◽  
...  
Keyword(s):  
Clinical Study ◽  
Glucose Tolerance ◽  
Er Stress ◽  
Glucose Tolerance Test ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Metabolic Phenotype ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Cross Sectional

Abstract Background Human data supporting a role for endoplasmic reticulum (ER) stress and calcium dyshomeostasis in diabetes is scarce. Darier disease (DD) is a hereditary skin disease caused by mutations in the ATP2A2 gene encoding the sarcoendoplasmic-reticulum ATPase 2 (SERCA2) calcium pump, which causes calcium dyshomeostasis and ER stress. We hypothesize that DD patients have a diabetes-like metabolic phenotype and the objective of this study was to examine the association between DD with impaired glucose tolerance and diabetes. Methods Cross-sectional clinical study on 25 DD patients and 25 matched controls. Metabolic status was assessed primarily by fasting blood glucose, oral glucose tolerance test, HOMA2-%S (insulin resistence) and HOMA2-%B (beta cell function). Results DD subjects showed normal oral glucose tolerance test and HOMA2-%S, while fasting blood glucose was lower and c-peptide as well as HOMA2-%B was higher. Conclusion Increased HOMA2-%B values are indicative of increased basal insulin secretion which is a type of beta cell dysfunction associated to diabetes development. These results supports a role of ER stress in diabetes pathophysiology and contribute to the understanding of DD as a multi-organ syndrome.

scholarly journals Lactobacillus rhamnosus Reduces Blood Glucose Level through Downregulation of Gluconeogenesis Gene Expression in Streptozotocin-Induced Diabetic Rats

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Eko Farida ◽  
Lilis Nuraida ◽  
Puspo E. Giriwono ◽  
Betty S. L. Jenie
Keyword(s):  
Blood Glucose ◽  
Glucose Tolerance ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Fasting Blood Glucose ◽  
Lactobacillus Rhamnosus ◽  
Tolerance Test ◽  
Diabetic Rats ◽  
The Body ◽  
Oral Glucose

Some lactic acid bacteria (LAB) are observed to be potential probiotics with functional properties such as lowering fasting blood glucose (FBG), as a promising hyperglycemia management. This study investigated the ability and mechanism of Lactobacillus rhamnosus BSL and Lactobacillus rhamnosus R23 on lowering FBG in diabetic rats induced by streptozotocin (STZ). The rats were orally administered with L. rhamnosus BSL and L. rhamnosus R23 by giving 1 mL cell suspension (109 CFU/mL) daily for 30 days. The body weight (BW) was recorded once in three days, and FBG was recorded once in six days. An oral glucose tolerance test (OGTT) was measured 1 week after injection with STZ and before sacrifice. Fecal samples were collected on days 0, 15, and 30 for LAB population and identification, performed by PCR detecting 16S rRNA. Oral administration of L. rhamnosus BSL and L. rhamnosus R23 decreased FBG and improved glucose tolerance via downregulation of glucose-6-phosphatase (G6pc) expression by 0.57- and 0.60-fold change, respectively (P<0.05). The lipid profiles, BUN, creatinine, SGOT, and SGPT were significantly (P<0.05) different between normal and diabetic rats, but they were not significantly (P>0.05) different among diabetic rats. Both strains were effective in increasing fecal LAB population. Molecular identification of the isolated LAB from fecal sample indicated that they were able to survive and pass through the digestive tract. These results suggested that both strains have the ability to manage blood glucose level and become a promising agent to manage hyperglycemia and diabetes.

Sign in / Sign up

Export Citation Format

Share Document